Amycretin’s Early Injection Trial: The Study That Opened the Door for Zenagamtide

The early Phase 1b/2a subcutaneous readout for Zenagamtide (formerly Amycretin / NNC0487-0111) provides critical proof-of-concept for the future of co-agonist pharmacology. By evaluating once-weekly administration of a single unimolecular peptide co-targeting the GLP-1 and amylin receptors over 36 weeks, these data demonstrate how simultaneous dual neuroendocrine pathway activation can unlock unprecedented weight reduction in early clinical development.

What Is the Compound? Unimolecular Dual GLP-1 and Amylin Co-Agonism Explained

Zenagamtide (originally designated as amycretin and coded as NNC0487-0111) is an investigational, unimolecular peptide co-agonist developed by Novo Nordisk. Unlike multi-drug combinations that co-formulate two separate peptide chains (such as CagriSema, which mixes the amylin analogue cagrilintide with the GLP-1 analogue semaglutide into a single syringe), zenagamtide is a single engineered chemical entity that simultaneously activates both the glucagon-like peptide-1 receptor (GLP-1R) and human amylin/calcitonin receptors (AMY1–3).

The molecular engineering behind unimolecular co-agonism addresses several pharmacokinetic and pharmacodynamic challenges:

• Synchronized Pharmacokinetics: In two-drug combinations, each peptide possesses its own independent clearance rate, volume of distribution, and tissue absorption curve. By fusing both pharmacophores into a single peptide backbone, zenagamtide delivers identical temporal receptor occupancy to both target pathways simultaneously.
• Complementary Dual Satiety Axes: GLP-1 receptor activation operates predominantly on the hypothalamic arcuate nucleus, slowing gastric emptying and dampening hunger cues. Concurrently, amylin agonism stimulates calcitonin/RAMP receptor complexes located in the area postrema and nucleus of the solitary tract (NTS) in the hindbrain, mimicking postprandial fullness and terminating meals without provoking aversive visceral malaise.
• Dual Formulation Pipeline: Reflecting Novo Nordisk’s oral peptide delivery platform, zenagamtide is undergoing parallel clinical development as both a once-weekly subcutaneous injection and a once-daily oral tablet co-formulated with the absorption enhancer SNAC.

The name change from amycretin to zenagamtide follows standard World Health Organization (WHO) International Nonproprietary Name (INN) adoption as the compound advances through development, with earlier trial disclosures remaining fundamental to understanding its biological activity.

How the Study Worked: Phase 1b/2a Dose-Escalation Architecture

The Phase 1b/2a trial was structured as a multi-part, double-blind, randomized, placebo-controlled proof-of-concept study to evaluate the safety, tolerability, pharmacokinetics, and preliminary weight-loss kinetics of subcutaneous zenagamtide:

Detailed study parameters and primary sponsor releases are documented in the Novo Nordisk Phase 1b/2a Primary Trial Announcement.

Results and Key Findings: High-Magnitude Early Weight Reduction

The 36-week primary proof-of-concept data from the 20 mg cohort demonstrated that unimolecular GLP-1/amylin co-agonism drives deep weight reduction in early-phase testing:

• 22.0% Mean Weight Loss at 36 Weeks: Participants in the 20 mg cohort achieved an estimated mean body weight loss of 22.0% under an on-treatment efficacy analysis, with expanded top-tier dose evaluations reaching up to 24.3%, compared to a 1.9% weight gain in the small matching placebo arm.
• Absence of an Efficacy Plateau: In contrast to standard incretin trials where weight-loss velocity slows substantially by week 32 to 36, the weight trajectory for zenagamtide continued on a downward trajectory through week 36, indicating that longer Phase 3 trials could yield even deeper reductions.
• Early-Phase Placebo Context: In small Phase 1 cohorts, placebo groups often exhibit minor weight fluctuations or slight weight gains (+1.9%) due to limited sample sizes. While this widens the net mathematical spread, the 22% gross drop remains one of the largest early-stage reductions recorded for a subcutaneous peptide.
• Comparison to Semaglutide and Tirzepatide: For historical context, weekly semaglutide 2.4 mg delivered ~15% weight loss at week 68 in STEP 1, while tirzepatide 15 mg achieved ~21% at week 72 in SURMOUNT-1. Achieving 22.0% in 36 weeks highlights the potency of adding amylin agonism to a GLP-1 backbone.

The Study in Plain English: Understanding Early Proof-of-Concept Trials

Interpreting early-phase clinical data requires understanding the distinction between an early proof-of-concept trial and a confirmatory Phase 3 study:

Key Insights: What Makes the Zenagamtide Phase 1b/2a Readout Critical?

The clinical contribution of this trial extends far beyond a compelling percentage, carrying profound implications for the future of multi-target peptides:

• Validation of the Unimolecular Strategy: Skeptics argued that fusing GLP-1 and amylin pharmacophores into a single peptide would cause steric hindrance, blunting receptor potency. The 22% weight reduction disproves this, proving that a unimolecular peptide can achieve equal or superior biological activity compared to two-drug combinations.
• Manufacturing and Formulation Advantages: Manufacturing and purifying one peptide is significantly more cost-effective and scalable than manufacturing two separate peptides (like cagrilintide and semaglutide) and co-formulating them into dual-chamber devices. A unimolecular peptide streamlines supply-chain production.
• Early-Phase Numbers Must Be Kept in Perspective: Early Phase 1/2 percentages have a documented history of regressing toward the mean when expanded to large, heterogeneous Phase 3 trials involving thousands of real-world patients. The appropriate takeaway is that zenagamtide possesses an exceptionally potent biological signal that justified immediate Phase 3 investment.

Tolerability & The Complete Safety Profile

Throughout the 36-week evaluation period, zenagamtide demonstrated a safety and adverse-event spectrum characteristic of the incretin class:

• Gastrointestinal Adverse Events: Consistent with GLP-1 and amylin receptor activation, mild-to-moderate nausea, vomiting, and diarrhea were the most common treatment-emergent adverse events (TEAEs), clustering primarily during initial dose titration.
• Discontinuation and Treatment Persistence: Adverse-event discontinuations were documented across dose tiers. While small cohort sizes limit statistical comparisons, tolerability was categorized by investigators as generally manageable and aligned with other incretin therapies.
• No Unpredicted Organ Toxicities: The sponsor reported no unexpected systemic toxicities, clinically significant hypoglycemia in non-diabetic cohorts, or laboratory-detected immunogenic anomalies.

For complete trial documentation and primary disclosures, reference the Novo Nordisk Primary Corporate Release and the Primary Scientific Poster Presentation.

Comparative Research Themes & Next-Generation Metabolic Pipelines

To contextualize zenagamtide within the broader landscape of obesity pharmacotherapy, researchers compare multi-receptor and amylin-based mechanisms:

For an in-depth review of unimolecular amylin/GLP-1 biology, explore our guide: Amycretin Beginner's Guide: Novo's GLP-1 + Amylin Dual Agonist. To evaluate selective amylin monotherapy data, read our analysis: Eloralintide Standalone Phase 2 Results: 48-Week Amylin Trial.

What Patients and Clinicians Can Look Forward To

Zenagamtide remains an investigational compound that is not yet approved by the U.S. FDA or international health authorities. However, following the completion of this Phase 1b/2a trial and parallel Phase 1 trials of its oral tablet formulation, Novo Nordisk has advanced zenagamtide into large-scale clinical development across both obesity and type 2 diabetes.

For clinicians and patients, zenagamtide represents the vanguard of single-molecule multi-pathway therapeutics. If confirmed in Phase 3 trials, an injectable or oral agent that pairs GLP-1 with amylin in a single molecule could offer higher efficacy than existing incretin monotherapies, streamlining obesity treatment into a more potent therapeutic option.

Questions for the Next Stage of Research

While the 36-week Phase 1b/2a findings provide strong proof-of-concept, several vital clinical questions guide the transition into late-stage trials:

• Confirmation in Phase 3 Cohorts: Will the 22% weight reduction persist in multi-thousand-patient, randomized, double-blind Phase 3 trials across diverse baseline populations?
• Long-Term Gastrointestinal Tolerability: How will adverse-event discontinuations and treatment persistence compare to CagriSema and tirzepatide when titrated over 52 to 72 weeks?
• Injectable vs. Oral Tablet Performance: How closely will the once-daily oral tablet formulation of zenagamtide match the weight-loss magnitude of the once-weekly subcutaneous injection?

Explore Our Research Tools

To assist laboratory scientists and clinicians in tracking peptide calculations, experimental schedules, and analytical observations, explore our specialized software suite:

• Calculate volume measurements and concentration parameters with the interactive Peptide Calculator.
• Structure research intervals, timing windows, and observation phases inside the Protocol Builder.
• Log laboratory markers, baseline patient metrics, and analytical notes with the Protocol Tracker Tool.

Scientific References & Primary Trial Documents

• Novo Nordisk: Subcutaneous Amycretin Phase 1b/2a Primary Clinical Trial Report (Press Release)
• Primary Scientific Poster: Efficacy and Safety of Subcutaneous Amycretin in Overweight and Obesity
• Amycretin Beginner's Guide: Novo's GLP-1 + Amylin Dual Agonist